These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32296987)

  • 21. Development and Optimization by Quality by Design Strategies of Frovatriptan Orally Disintegrating Tablets for Migraine Management.
    Mennini N; Orlandini S; Furlanetto S; Pasquini B; Mura P
    Curr Drug Deliv; 2018; 15(3):436-445. PubMed ID: 28595529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel and discriminative method of in vitro disintegration time for preparation and optimization of taste-masked orally disintegrating tablets of carbinoxamine maleate.
    Liu Y; Li P; Qian R; Sun T; Fang F; Wang Z; Ke X; Xu B
    Drug Dev Ind Pharm; 2018 Aug; 44(8):1317-1327. PubMed ID: 29521132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation and evaluation of novel multi-channel orally disintegrating tablets.
    Yu J; Shan X; Chen S; Sun X; Song P; Zhao R; Hu L
    Eur J Pharm Sci; 2020 Jan; 142():105108. PubMed ID: 31669391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deacetyl Mycoepoxydience Nanocrystals Dispersible Tablets Formulation and
    Du J; Zhou Y; Wang L; Zhao J; Liu Y; Li C; Wang Y
    J Nanosci Nanotechnol; 2018 Jun; 18(6):3850-3855. PubMed ID: 29442718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability.
    Dennison TJ; Smith JC; Badhan RK; Mohammed AR
    Drug Des Devel Ther; 2017; 11():811-826. PubMed ID: 28352156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enalapril maleate orally disintegrating tablets: tableting and in vivo evaluation in hypertensive rats.
    Tawfeek HM; Faisal W; Soliman GM
    Pharm Dev Technol; 2018 Jun; 23(5):496-503. PubMed ID: 28489472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and optimization of lyophilized orally disintegrating tablets using factorial design.
    Ahmed IS; Shamma RN; Shoukri RA
    Pharm Dev Technol; 2013; 18(4):935-43. PubMed ID: 22107175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges and emerging solutions in the development of compressed orally disintegrating tablets.
    Al-Khattawi A; Mohammed AR
    Expert Opin Drug Discov; 2014 Oct; 9(10):1109-20. PubMed ID: 25045997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo correlation of disintegration and bitter taste masking using orally disintegrating tablet containing ion exchange resin-drug complex.
    Kim JI; Cho SM; Cui JH; Cao QR; Oh E; Lee BJ
    Int J Pharm; 2013 Oct; 455(1-2):31-9. PubMed ID: 23933050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of screw configuration and polymeric carriers on hot-melt extruded taste-masked formulations incorporated into orally disintegrating tablets.
    Morott JT; Pimparade M; Park JB; Worley CP; Majumdar S; Lian Z; Pinto E; Bi Y; Durig T; Repka MA
    J Pharm Sci; 2015 Jan; 104(1):124-34. PubMed ID: 25410968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The improvement of the dissolution rate of ziprasidone free base from solid oral formulations.
    Zakowiecki D; Cal K; Kaminski K; Adrjanowicz K; Swinder L; Kaminska E; Garbacz G
    AAPS PharmSciTech; 2015 Aug; 16(4):922-33. PubMed ID: 25588366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tablet characteristics and pharmacokinetics of orally disintegrating tablets containing coenzyme Q10 granules prepared by different methods.
    Kashiwagura Y; Takusagawa S; Ikematsu Y; Tanaka S; Namiki N; Uchida S
    Acta Pharm; 2023 Mar; 73(1):107-119. PubMed ID: 36692467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new modified wetting test and an alternative disintegration test for orally disintegrating tablets.
    Hooper P; Lasher J; Alexander KS; Baki G
    J Pharm Biomed Anal; 2016 Feb; 120():391-6. PubMed ID: 26774944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Formulation and Evaluation of Loperamide HCl Oro Dispersible Tablets.
    Alejandro B; Guillermo T; Ángeles PM
    Pharmaceuticals (Basel); 2020 May; 13(5):. PubMed ID: 32443638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coated dextrin microcapsules of amlodipine incorporable into orally disintegrating tablets for geriatric patients.
    Jang DJ; Bae SK; Oh E
    Biomed Pharmacother; 2014 Oct; 68(8):1117-24. PubMed ID: 25458788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, Formulation, and Physicochemical Evaluation of Montelukast Orally Disintegrating Tablet.
    Aslani A; Beigi M
    Int J Prev Med; 2016; 7():120. PubMed ID: 27857833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables.
    Mostafa HF; Ibrahim MA; Sakr A
    Pharm Dev Technol; 2013; 18(2):454-63. PubMed ID: 22881389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Application of β-cyclodextrin in the formulation of ODT tablets containing ibuprofen].
    Zimmer Ł; Kasperek R; Poleszak E
    Polim Med; 2014; 44(4):231-5. PubMed ID: 25932904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Orally disintegrating tablets and orally disintegrating mini tablets - novel dosage forms for pediatric use.
    Comoglu T; Dilek Ozyilmaz E
    Pharm Dev Technol; 2019 Sep; 24(7):902-914. PubMed ID: 31215850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets.
    Lai F; Pini E; Angioni G; Manca ML; Perricci J; Sinico C; Fadda AM
    Eur J Pharm Biopharm; 2011 Nov; 79(3):552-8. PubMed ID: 21820052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.